Dry Eyes and Nosebleeds During Isotretinoin: What the Studies Show

By Michael Wiederkehr, M.D.

Dry lips are an expected part of many conversations about isotretinoin. Dry eyes, nasal crusting, and recurrent nosebleeds are sometimes discussed less clearly, even though they can interfere with reading, wearing contact lenses, sleeping, working, or simply feeling comfortable. A symptom does not become unimportant because other patients report it too.

The useful distinction is between a symptom that can be managed within an agreed care plan and a change that requires prompt assessment. Calling everything "normal dryness" obscures that distinction. Calling every episode a sign of permanent damage obscures it in the opposite direction.

The relevant clinical evidence includes an ocular systematic review and a prospective investigation of nasal symptoms. Together they show why patient-reported discomfort, clinical findings, and physiological measurements should be interpreted alongside one another. Further primary studies and official eye-care information help translate those findings into practical questions.

This article explains the evidence, common terminology, supportive care principles, and warning signs. It does not identify the cause of an individual reader's symptoms or prescribe changes to an isotretinoin course. The examples are hypothetical and intended to show how to describe a problem accurately.

Why dryness is more than a skin issue

The eye surface and nasal lining need an appropriate local environment to remain comfortable and function well. Isotretinoin-associated effects are therefore not limited to visible facial peeling. The current prescribing information lists dry eye and epistaxis, the medical term for nosebleeding, among commonly reported adverse reactions. ^[1]

That statement identifies recognized effects; it does not establish that every eye or nasal symptom during treatment has the same cause. Allergy, infection, contact lens problems, other medicines, environmental conditions, and pre-existing disease may also be relevant. A complete account should leave room for these possibilities.

A person may describe several experiences with the word "dry": a gritty sensation, burning, a feeling of tightness, crusting, intermittent irritation, or difficulty tolerating a previously comfortable activity. The clinician needs to know which experience is present. The word alone is a starting point rather than a diagnosis.

This is why practical questions often matter more than a broad label. Does the symptom affect one eye or both? Is the nosebleed occasional or recurrent? Is vision actually changing? Does discomfort occur after contact lens use? Has the symptom become more intense or more frequent?

A care plan should make room for these details from the beginning. If patients are told only that dryness is common, they may assume there is no point reporting it. A better explanation says what can be discussed at routine review, what deserves earlier contact, and what requires urgent assessment.

The tear film: enough tears is only part of the question

The National Eye Institute explains that dry eye can occur when the eyes do not make enough tears or when the tears do not work properly, including when they evaporate too quickly. ^[2] This means that tear quantity and tear-film performance are related but separate questions.

The meibomian glands in the eyelids contribute to the oily component of the tear film. Studies of isotretinoin have examined changes in these glands and the stability of tears. A 2022 prospective pilot study involving 30 patients reported findings consistent with meibomian gland dysfunction and evaporative dryness. ^[3]

A simplified comparison is a surface that becomes wet but does not remain evenly covered. Adding fluid may temporarily help, while the reason it fails to stay stable still needs consideration. This analogy explains why the assessment may include eyelids and tear stability rather than only a measurement of tear volume.

The distinction can also explain why a patient feels that "I have tears, so I cannot have dry eye" does not settle the issue. A visible tear response is not a complete test of tear-film function. Similarly, the absence of obvious redness does not establish that the surface is comfortable or functioning normally.

The mechanism should not be overstated. Finding gland changes in a study does not prove that every reader has the same changes, that every change is permanent, or that one examination can predict the entire future course. It provides a biologically relevant question for assessment.

What the ocular systematic review contributes

The 2023 systematic review included 53 original studies in its meta-analysis and 41 case reports or series in its narrative assessment. Dry eye was the most commonly reported ocular effect. The review also addressed sensitivity, inflammatory conditions, and vision-related changes. ^[4]

The breadth of the review is useful, but it introduces variation. Researchers used different symptom descriptions, tests, regimens, and follow-up periods. A pooled result does not become a universal forecast simply because several studies were combined. The definition of the outcome remains important.

An article should therefore resist giving one apparently precise percentage for "eye problems" without explaining what the percentage includes. A symptom reported on a questionnaire, a change in tear breakup time, and a diagnosed inflammatory condition are different observations. Combining them under one vague label can mislead.

The two parts of the review also serve different purposes. Original studies can contribute to estimates under their sampling methods. Case reports can describe unusual presentations and possible concerns, but they cannot independently show how often those concerns occur among all treated people.

The review supports taking ocular symptoms seriously and recognizing variation in presentation. It does not justify telling every patient to expect the same severity or the same recovery timeline. A useful practical response is to ask about baseline eye health, describe new symptoms accurately, and obtain assessment when the pattern calls for it.

Understanding the common eye tests

The National Eye Institute describes several ways of evaluating dry eye, including measurements of tear production, tear stability, and the condition of the eyelids. Schirmer testing examines tear production, while tear breakup time assesses how long the film remains stable after a blink. ^[5]

The table explains why there is no single "dryness number" that answers everything. Different tests are complementary. A clinician may choose some and not others depending on the problem being assessed.

Patients should ask what a result means in their case rather than comparing it directly with a value from a research paper. Test technique, population, and measurement conditions can differ. A number outside a published study average does not automatically indicate a more severe condition.

The examination also has a different purpose from routine isotretinoin blood testing. A normal lipid or liver panel cannot evaluate tear-film stability or explain an eye symptom. If an ocular problem is the concern, the appropriate assessment needs to address the eye itself.

Symptoms and objective findings do not always match neatly

A patient may have substantial discomfort with modest changes in one measured test. Another may have a measurable change with fewer symptoms. These situations require interpretation rather than a contest over whether the patient or the test is "right."

The symptom and the measurement answer different questions. One describes experience and function. The other samples a physiological property under examination conditions. A disagreement can identify the need for more context, a different assessment, or follow-up; it does not automatically invalidate either source of information.

Imagine a hypothetical office worker who can read comfortably in the morning but struggles after several hours at a screen. An examination at another time may not reproduce the worst period. The account of when symptoms occur helps connect the clinical visit to the actual daily problem.

Another patient may report that eye discomfort has improved after changing an activity while a measured finding remains altered. That does not prove the finding has no significance. It creates a follow-up question about how symptoms and signs are evolving together.

Good documentation therefore includes both: "The test showed this, and the patient reports this effect on daily life." Reducing the record to either a questionnaire score or a single examination number can lose information needed for management.

This principle is especially relevant when reading research. A study that reports improved comfort has not necessarily demonstrated normalization of gland structure. A study that reports a structural change has not necessarily demonstrated permanent functional impairment. The endpoint must remain visible in the interpretation.

What studies of meibomian glands can and cannot tell us

A 2023 prospective study examined ocular surface and gland characteristics during and after isotretinoin. It reported increased complaints associated with changes in the lipid component of the tear film and observed reversible changes in gland morphology and function over its follow-up. ^[6]

That is useful evidence about the participants and time points studied. It should not become a promise that every patient will recover completely within an identical interval. The observation window, sample, baseline condition, and measured outcomes all limit that conclusion.

Other longitudinal and prospective studies have evaluated tear-film and gland changes with different methods and patient groups. ^[7][8] Their existence strengthens the case for examining this part of the ocular surface, but differences between studies make a single universal timeline inappropriate.

When a person asks whether symptoms will persist, there are several distinct questions:

• Are symptoms improving, stable, or worsening now?
• Is the examination showing an ongoing problem?
• Was there an eye condition before treatment?
• What supportive care has actually been tried under guidance?
• What follow-up interval is appropriate?
• Is another diagnosis or contributing factor being considered?

These questions are more useful than assuming that a study's average follow-up result determines one person's outcome. They also prevent a false choice between absolute reassurance and a prediction of permanent harm.

A responsible article should state the evidence's limits openly. Persistent symptoms deserve care even when recovery is common in some studies, while uncertainty about long-term outcomes should not be converted into an unsupported claim of inevitable damage.

Contact lenses can change the practical impact

Contact lens wear is relevant to dry-eye assessment, and eye-care guidance advises using lens products and drops appropriate for the individual lens and eye-care plan. ^[9][10] A lens that was comfortable before treatment may become harder to tolerate if the ocular surface changes.

The practical issue is not simply whether lenses are "allowed." It is whether they remain comfortable and safe in the current circumstances. A person should not push through pain, substantial redness, or a visual change merely because the same lenses were previously tolerated.

Having usable glasses available can make it easier to respond to discomfort without feeling forced to continue wearing lenses. This is a planning suggestion, not a requirement that every lens wearer abandon lenses for the entire course. The eye-care clinician can advise on the actual situation.

Patients should also distinguish a lubricant compatible with contact lenses from a product that is not intended for use while lenses are in place. The words "eye drops" cover many products with different ingredients and instructions. Product choice should follow the label and professional advice.

Useful information to bring to the appointment includes the lens type, usual wearing time, cleaning system, replacement schedule, and whether symptoms occur with or without lenses. The goal is to identify the actual pattern, not assume that the lens is either entirely responsible or entirely irrelevant.

Routine lens hygiene remains important. A prescription medicine does not change the need to follow the approved cleaning and replacement instructions. Discomfort should trigger reassessment, not shortcuts in lens care or experiments with products found online.

Screen work and the environment: contributors rather than complete explanations

The American Academy of Ophthalmology discusses how prolonged device use and reduced blinking can contribute to eye strain and dry-eye symptoms. ^[11] Environmental factors such as moving air can also matter in dry-eye care. ^[2]

For a person taking isotretinoin, this means several contributors may overlap. The medicine may be part of the picture while work habits and surroundings influence when symptoms are most noticeable. Identifying a modifiable contributor does not prove that the treatment has no role.

A practical review can start with ordinary observations: Is discomfort worse near a fan or air vent? Does it increase during long periods of concentrated reading? Is there a difference between workdays and days away from the screen? These observations can guide a discussion without requiring formal self-experiments.

Breaks from prolonged screen concentration and attention to blinking may be useful components of an agreed plan. They should not replace assessment when symptoms persist or affect vision. A person who is struggling to perform daily tasks needs more than a reminder to use the computer less.

Nor should workplace advice become an unrealistic demand. Many people cannot avoid screens for their job. The useful goal is a workable plan involving the ocular assessment, appropriate supportive treatment, and feasible changes to the environment or routine.

The standard for success should be meaningful function: comfortable reading, tolerable work, safe driving, or manageable symptoms. A plan that technically exists but cannot be followed in daily life needs revision with the clinician.

Choosing eye drops: categories matter

Artificial tears are a common first approach for mild dry eye, but "drops" are not one interchangeable category. Lubricants, redness-relieving products, allergy treatments, and prescription medicines have different purposes. The American Academy of Ophthalmology distinguishes lubrication from simply reducing visible redness. ^[12][13]

The choice of a product should match the problem being treated. A product marketed to make the eye look whiter does not necessarily address the cause of discomfort. Repeatedly adding products without a plan can make it harder to identify what helps or what causes irritation.

The table is not a shopping guide. It explains why selecting a category by advertising language can be misleading. A pharmacist or eye-care clinician can help interpret the product instructions, especially for contact lens users or people using several eye medicines.

If symptoms are persistent, worsening, or affecting daily life, assessment is more useful than cycling through increasingly expensive lubricants. Lack of benefit is information to report, including the exact product and how it was used.

Eye-drop hygiene is part of treatment

FDA advises washing hands before using eye drops and avoiding contact between the bottle tip and the eye, hands, clothing, or other surfaces. Eye products need to remain appropriately sterile, and consumers should follow product instructions and relevant safety notices. ^[14]

These are small procedural details with a clear purpose: preventing contamination. They should not be treated as optional because a product is sold without prescription or described as gentle. The route of administration makes the quality and handling of the product important.

Keep the original packaging or enough identifying information to tell the clinician which product is being used. If a problem appears after starting a new bottle, the name, ingredients, lot details where available, and opening date may be useful information. Do not rely on a description such as "the blue bottle."

Avoid sharing eye drops with another person. A product that helped a friend does not establish suitability for a different problem, and shared handling introduces additional uncertainty. The same logic applies to using leftover prescription eye medicines without current advice.

The aim is a simple, consistent routine that follows instructions. Patients should not need an elaborate collection of products to manage ordinary treatment-related discomfort. If the routine keeps expanding without adequate relief, the next step is reassessment rather than continued accumulation.

The nasal study: a closer look at the actual participants

The nasal investigation initially enrolled 54 people with severe acne. Twelve stopped isotretinoin because of adverse effects. Subjective assessments were completed in 42 participants and objective testing in 32 at the specified time points. Dryness, crusting, and epistaxis became more prominent during follow-up. ^[15]

Those denominators matter. Saying "54 patients were followed with all tests" would overstate the complete observations. Attrition can affect interpretation because people who stop treatment may differ from those who remain. A careful summary retains the actual numbers rather than using only the enrollment figure.

The study also compared subjective nasal obstruction with objective measures such as nasal resistance. Symptom scores increased, while the measured resistance changes were not statistically significant. ^[15] That finding does not make the reported obstruction imaginary. It shows that the selected measurements did not move in an identical way.

The study is useful because it asks about a practical problem that may otherwise be dismissed as minor. Its size, short follow-up, and incomplete objective testing limit broad estimates. It does not provide a universal probability of nosebleeding for every dose, population, or course duration.

For the patient, the relevant lesson is descriptive: mention dryness and crusting as well as bleeding or blockage. These may be related experiences, but the clinician should know which ones occur, how often, and how much they interfere with daily life.

Crusting, irritation, and obstruction are separate symptoms

A person may use "blocked nose" to describe several different sensations. There may be crusting, dryness, irritation, or another process. The symptom should be described in its own terms rather than translated immediately into a conclusion about airflow or anatomy.

A useful account might say, "It feels blocked when the inside is crusted, and I notice small amounts of blood when I disturb it." Another might say, "There is persistent one-sided obstruction even when there is no crusting." These are different stories and may lead to different questions.

The nasal study's disagreement between symptom scores and measured resistance illustrates why a single test cannot summarize the entire experience. The test captures the property it measures. The patient captures discomfort and function. Clinical interpretation connects the two.

It also helps to distinguish prevention from treatment of an active bleed. Measures intended to reduce dryness are not automatically appropriate as first aid during bleeding. First aid has a different immediate goal and should follow established guidance.

Patients should ask before applying unfamiliar products inside the nose. A facial moisturizer, essential oil, or skin treatment is not necessarily intended for nasal use. The fact that two body surfaces feel dry does not make their product requirements identical.

Recurrent symptoms, significant discomfort, or an unusual pattern should be discussed with the prescriber or appropriate clinician. The aim is to identify a practical care plan and determine whether further assessment is needed, rather than assume that every nasal problem is an unavoidable part of the course.

What to do during a nosebleed

NHS guidance advises sitting down, leaning forward with the mouth open, and pinching the soft part of the nose just above the nostrils continuously for 10 to 15 minutes while breathing through the mouth. It advises urgent assessment for prolonged or excessive bleeding, weakness or dizziness, difficulty breathing, bleeding after a head injury, or swallowing enough blood to cause vomiting. ^[16]

The posture matters because leaning backward sends blood toward the throat rather than helping the person manage it safely. The pressure needs to be continuous rather than repeatedly released every few seconds to check whether the bleeding has stopped.

Local urgent-care arrangements vary by country. A person with significant bleeding or associated concerning symptoms should use the appropriate local emergency service rather than wait for a routine dermatology reply. A medication-related explanation does not remove the need to assess the severity of the bleeding itself.

If bleeding recurs, report the frequency and approximate duration, whether it is consistently one-sided, and any other relevant medicines or bleeding history. A short record is enough. Do not delay necessary care to complete a diary or calculate blood loss precisely.

The first-aid instructions are for an active episode. A longer-term plan may address dryness, recurring irritation, or another cause after assessment. Confusing those two plans can lead a person to apply a moisturizing product while neglecting the sustained pressure needed during the bleed.

When an eye symptom should not be treated as routine dryness

The isotretinoin label includes warnings about visual disturbances, including decreased night vision. It advises discontinuation and ophthalmological assessment if visual symptoms occur. ^[1] A reader should not assume that a new visual change can safely be managed by adding lubricant and waiting until the course ends.

Significant eye pain, marked redness, or a new change in vision requires prompt assessment through an appropriate service. This is particularly important when a person wears contact lenses, because the differential diagnosis includes problems beyond simple dryness. ^[13][17]

This table is a communication guide, not a remote triage diagnosis. If the person is uncertain whether a symptom is urgent, contacting an appropriate medical service is preferable to relying on a generalized online comparison.

A practical baseline conversation

Before or early in treatment, mention previous dry eye, contact lens intolerance, eye surgery, existing eye medicines, recurrent nosebleeds, and persistent nasal complaints. These details can change what monitoring or supportive care is appropriate. They also establish a baseline for comparison.

The goal is not to order every available test for every patient. It is to identify the questions already present. A person with no ocular symptoms and a person receiving active treatment for an eye condition should not be assumed to have identical needs.

A concise baseline discussion can cover:

1. Which symptoms already exist?
2. Which professional is managing them?
3. What medicines, drops, sprays, or devices are being used?
4. Which activities are most important to preserve?
5. What changes should prompt earlier contact?
6. What is the route for an urgent eye or bleeding concern?

The activity question makes the plan practical. A person who drives at night, wears lenses for work, or studies on a screen may need to understand how to respond if symptoms interfere. This is not about predicting that a problem will occur; it is about avoiding uncertainty if it does.

Patients should not independently add vitamin A because a general dry-eye page discusses nutrition. Isotretinoin labeling advises avoiding concomitant vitamin A supplementation because of additive adverse effects. ^[1] General nutrition information must be interpreted in the context of the actual medicine.

A symptom record that remains manageable

A useful record focuses on changes that affect interpretation. It does not require a daily score for every sensation. Overly detailed logging can become burdensome without adding information that changes care.

The record should include what actually happened, not a conclusion about causation. "Symptoms began after a dose change" is useful timing information. "The dose definitely damaged my eyes" is a causal conclusion that requires assessment.

Likewise, improvement after a supportive measure does not prove the entire mechanism. It can still be valuable evidence that the measure helped the person's comfort. Clinical care often proceeds by combining such observations with examination and follow-up rather than waiting for certainty about every contributor.

Comparing supportive approaches by purpose

Supportive measures should be compared according to their purpose, not ranked as though one is universally strongest. The choice depends on what is being treated and whether the diagnosis is established.

The comparison helps avoid a common mistake: expecting a supportive product to answer a diagnostic question. If an eye symptom is actually a visual disturbance, the priority is assessment. If a nosebleed is excessive, the priority is controlling bleeding and obtaining appropriate care.

A plan can combine several approaches, but each should have a reason. If every new symptom results in another product without a review of the pattern, the treatment routine may become complicated while the underlying question remains unresolved.

Five situations that deserve different conversations

The screen worker with afternoon irritation

A hypothetical patient has mild bilateral grittiness after several hours of screen work and no reported visual change. The useful conversation includes the ocular surface, work pattern, lens use, current products, and the effect on function. It should produce an achievable plan and a review point.

The contact lens wearer with a painful red eye

Another patient assumes discomfort is expected and keeps wearing lenses. Pain and redness should not be normalized simply because isotretinoin can cause dryness. The problem needs prompt appropriate assessment, with the contact lens history clearly reported.

The patient with recurrent small nosebleeds

A third person has repeated brief episodes and crusting. The frequency and local symptoms deserve review, even if each bleed stops. The discussion should distinguish management during an episode from prevention and possible investigation afterward.

The patient with new night-vision difficulty

A fourth person notices difficulty driving after dark. This belongs in the visual-disturbance pathway described by the product information, rather than the routine "dry eyes" conversation. The actual functional change should be reported promptly and unsafe driving avoided.

The patient whose symptoms persist after the course

A fifth person expects immediate resolution and becomes worried when discomfort continues. Persistence deserves follow-up rather than a promise based on another person's timeline. The clinician can assess the present condition and other contributors instead of assuming either inevitable permanence or guaranteed rapid recovery.

These examples show why the same broad side-effect category contains different clinical questions. The goal is a proportionate response based on the actual presentation.

Frequently asked questions

Making the next appointment useful

Bring a short symptom timeline, the names of eye and nasal products, and any relevant eye-care history. Identify the activity most affected: reading, contact lens wear, night driving, sleep, or another daily task. That gives the clinician a concrete outcome to improve rather than a vague request to eliminate every sensation of dryness.

Ask what the working explanation is, what remains uncertain, and when the response should be reviewed. If an eye referral is recommended, clarify whether it is routine or urgent and what to do while waiting. If a medication instruction is given, record it accurately instead of inferring it from the tone of the conversation.

The research supports a serious but proportionate approach. Dryness is recognized, symptoms and tests can differ, and small studies cannot predict every individual course. The practical goal is comfortable, functional, monitored treatment with a clear response to new or worsening problems. That goal is more useful than treating all symptoms as either harmless or catastrophic.

Evaluating whether the plan is working

A follow-up plan needs an outcome that the patient can recognize. "Use this and see how it goes" leaves several questions unanswered. The person should know what improvement is expected, what would count as an inadequate response, and when to contact the service again. This is especially useful when symptoms fluctuate, because a single comfortable day may not represent a sustained improvement.

A practical outcome could be longer comfortable reading, fewer interrupted work periods, less frequent bleeding, or improved tolerance of an activity after professional advice. These are examples of patient-centered goals, not promises about a specific treatment. They allow the next discussion to focus on what changed rather than merely whether a product was purchased.

It also helps to distinguish a treatment trial from indefinite self-treatment. If a clinician recommends a measure, ask how long it should be used before its effect is reviewed. If the measure causes irritation or another new problem, ask how to report that and whether it should be stopped. The instructions should come from the actual professional plan and product information, not a generic schedule copied from another person's experience.

When several products are involved, bring them or their labels to the review. Two bottles with different names may contain overlapping ingredients, while similarly named products may serve different purposes. An accurate list can simplify the routine and clarify which part is intended to address which symptom.

Finally, review the original reason for concern. If the problem was a visual change, temporary comfort after a lubricant does not close that question. If the problem was repeated bleeding, a symptom-free morning does not describe the whole week. Assessing the relevant outcome prevents partial relief from being mistaken for a complete explanation. The aim is a plan that can be judged against the problem it was designed to address.

References

1. Isotretinoin capsules prescribing information, revised August 2026. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=1cf11710-f966-4529-8e08-02175f588bca
2. National Eye Institute. Dry Eye. https://www.nei.nih.gov/eye-health-information/eye-conditions-and-diseases/dry-eye
3. The effect of isotretinoin on meibomian glands in eyes: a pilot study. https://pubmed.ncbi.nlm.nih.gov/34978652/
4. Ocular side effects of systemic isotretinoin: a systematic review and summary of case reports. 2023. https://pubmed.ncbi.nlm.nih.gov/37248700/
5. National Eye Institute. Testing for Dry Eye. https://www.nei.nih.gov/eye-health-information/eye-conditions-and-diseases/dry-eye/testing-dry-eye
6. The Effect of Oral Isotretinoin Therapy on Meibomian Gland Characteristics in Patients with Acne Vulgaris. 2023. https://pubmed.ncbi.nlm.nih.gov/37301783/
7. Longitudinal assessment of meibomian glands and tear film layer in systemic isotretinoin treatment. https://pubmed.ncbi.nlm.nih.gov/34011178/
8. The impact of systemic isotretinoin treatment on the tear film, meibomian glands, and corneal endothelium. 2024. https://pubmed.ncbi.nlm.nih.gov/38873903/
9. National Eye Institute. Contact Lenses. https://www.nei.nih.gov/eye-health-information/healthy-vision/contact-lenses
10. FDA. Contact Lens Care. https://www.fda.gov/consumers/womens-health-topics/contact-lens-care
11. American Academy of Ophthalmology. Computers, Digital Devices, and Eye Strain. https://aao.org/eye-health/tips-prevention/computer-usage
12. American Academy of Ophthalmology. Redness-Relieving Eye Drops. https://aao.org/eye-health/drugs/redness-relieving-eye-drops
13. American Academy of Ophthalmology. What Is Dry Eye? https://aao.org/eye-health/diseases/what-is-dry-eye
14. FDA. What You Should Know about Eye Drops. https://www.fda.gov/drugs/buying-using-medicine-safely/what-you-should-know-about-eye-drops
15. Effects of oral isotretinoin therapy on the nasal cavities. https://pubmed.ncbi.nlm.nih.gov/30472003/ ; supplementary dataset: https://figshare.com/articles/dataset/12056538
16. NHS. Nosebleed. https://www.nhs.uk/conditions/nosebleed/
17. National Eye Institute. Corneal Conditions. https://www.nei.nih.gov/eye-health-information/eye-conditions-and-diseases/corneal-conditions